References
- Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41:401–7.
- Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65:137–74.
- Griffiths CEG, Barnes MR, Burden AD, et al. Establishing an academic–industrial stratified medicine consortium: psoriasis stratification to optimize relevant therapy. J Invest Dermatol. 2015;135:2903–7.
- Gedebjerg A, Johansen C, Kragballe K, et al. IL-20, IL-21 and p40: potential biomarkers of treatment response for Ustekinumab. Acta Derm Venereol. 2013;93:150–5.
- Talamonti M, Botti E, Galluzzo M, et al. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab. Br J Dermatol. 2013;169:458–63.
- Clark L, Lebwohl M. The effect of weight on the efficacy of biologic therapy in patients with psoriasis. J Am Acad Dermatol. 2008;58:443–6.
- Puig L. Obesity and Psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol. 2011;25:1007–11.
- Griffiths CEM, Christophers E, Szumski A, et al. Impact of early vs. late disease onset on treatment response to etanercept in patients with psoriasis. Br J Dermatol. 2015; 173:1271–3.
- García-Doval I, Pérez-Zafrilla B, Ferrandiz C, et al. Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort. J Dermatolog Treat. 2016;27:203–9.
- Zhu B, Edson-Heredia E, Cameron G, et al. Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase 2 study of patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2013;169:1337–41.
- Papp KA, Menter A, Strober B, et al. Efficacy and safety of Tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol. 2012;167:668–77.
- Papp KA, Menter MA, Abe M, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol. 2015;173:949–61.
- Gordon K, Strober B, Tan H, et al. Early clinical response as a predictor of efficacy in moderate to severe psoriasis patients treated with tofacitinib in a phase 2 study. J Am Acad Dermatol. 2015;72:AB231.
- Youden WJ. Index for rating diagnostic tests. Cancer 1950;3:32–5.
- Tan H, Gupta P, Harness J, et al. Dose response and pharmacokinetics of Tofacitinib (CP-690,550), and oral Janus kinase inhibitor, in the treatment of chronic plaque psoriasis. cpt: PSP 2013;2:e44.
- Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303:1–10.